Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

Heart failure, a condition where the heart struggles to pump blood efficiently to meet the body's needs, comes in various forms and one of them, heart failure with preserved ejection fraction ...

This category was introduced as HF with "mid-range" ejection fraction -- 40-49% -- in the 2016 European Society of Cardiology heart failure guidelines before being christened HF with mildly ...

Part 3: Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation. Part 4: Case Study: Lightheadedness, Fatigue in Man With Hypertension. Up next: Medical Management ...

Lungs Heart The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes. Full results from the phase 3 ...

They had New York Heart Association (NYHA) class II, III, or IV heart failure and an ejection fraction of 40% or less. Half of the patients had diabetes, ...